Oruka Therapeutics (NASDAQ:ORKA) Reaches New 52-Week High - What's Next?

Key Points

• Oruka Therapeutics reached a new 52-week high of $112.01, giving the company a market capitalization of approximately $7.28 billion. Shares were recently trading near $110, well above their 50-day and 200-day moving averages.
• Analyst sentiment remains broadly positive, with 10 Buy ratings and one Sell rating. The consensus rating is “Moderate Buy,” with an average price target of $134.30 and individual targets ranging from $120 to $200.
• The clinical-stage biotechnology company reported a quarterly loss of $0.55 per share, missing estimates by $0.04, while insiders sold $12.05 million of stock over the past three months. Oruka’s lead candidate, ONCT-01, is in Phase 1 trials for advanced solid tumors.

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) reached a new 52-week high during trading on Monday . The company traded as high as $112.01 and last traded at $110.1360, with a volume of 2880 shares changing hands. The stock had previously closed at $111.04.

Analysts Set New Price Targets

A number of equities analysts recently commented on ORKA shares. HC Wainwright reaffirmed a "buy" rating and set a $120.00 price target on shares of Oruka Therapeutics in a research note on Monday, August 3rd. BTIG Research reaffirmed a "buy" rating and set a $151.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Guggenheim reissued a "buy" rating and issued a $200.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Piper Sandler restated an "overweight" rating and set a $180.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, June 2nd. Finally, Barclays lifted their target price on Oruka Therapeutics from $78.00 to $160.00 and gave the company an "overweight" rating in a research report on Monday, April 27th. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $134.30.

Oruka Therapeutics Trading Down 0.9%

The company has a market capitalization of $7.28 billion, a price-to-earnings ratio of -54.18 and a beta of -0.34. The company has a 50-day moving average of $87.52 and a 200-day moving average of $62.81.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.04). On average, research analysts expect that Oruka Therapeutics, Inc. will post -2.27 EPS for the current year.

Insider Activity at Oruka Therapeutics

In other news, CEO Lawrence Otto Klein sold 1,729 shares of the business's stock in a transaction on Monday, June 15th. The shares were sold at an average price of $69.69, for a total transaction of $120,494.01. Following the sale, the chief executive officer directly owned 925,580 shares of the company's stock, valued at $64,503,670.20. The trade was a 0.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Arjun Agarwal sold 10,000 shares of the company's stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $106.66, for a total value of $1,066,600.00. Following the completion of the transaction, the senior vice president directly owned 15,312 shares in the company, valued at approximately $1,633,177.92. The trade was a 39.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 181,116 shares of company stock valued at $12,045,503 over the last three months. 23.49% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ORKA. Algert Global LLC boosted its holdings in shares of Oruka Therapeutics by 3.5% in the 2nd quarter. Algert Global LLC now owns 5,380 shares of the company's stock valued at $512,000 after acquiring an additional 180 shares during the last quarter. Royal Bank of Canada grew its holdings in Oruka Therapeutics by 47.2% during the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company's stock worth $34,000 after acquiring an additional 365 shares during the period. Kennedy Capital Management LLC boosted its holdings in Oruka Therapeutics by 0.9% in the 4th quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company's stock worth $1,476,000 after buying an additional 420 shares during the last quarter. AlphaCentric Advisors LLC raised its stake in Oruka Therapeutics by 5.8% in the 1st quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company's stock valued at $564,000 after purchasing an additional 626 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in shares of Oruka Therapeutics by 35.0% in the fourth quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company's stock valued at $92,000 after purchasing an additional 788 shares during the last quarter. 56.44% of the stock is owned by institutional investors and hedge funds.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source